18 F-FCH PET/CT Localizes Ectopic Parathyroid Adenoma.

Clin Nucl MedJul 7, 2026 (epub)
Case ReportNuclear MedicineEndocrinologyGeneral Surgery

Gangjuan Sun, Nachuan Cao, Qiaoqiao Shu et al.

✦ AI-curated · Sources linked

Case in brief

An 18-year-old man presented with hypercalcemia and suspected primary hyperparathyroidism. Thyroid ultrasound showed no significant abnormality, but ectopic parathyroid hyperfunction remained possible. 18F-fluoromethylcholine PET/CT identified increased tracer uptake in the anterior superior mediastinum, suggesting an ectopic parathyroid adenoma. Imaging guided minimally invasive excision, and postoperative pathology confirmed the diagnosis.

What made this case unusual

The suspected adenoma was ectopic and located in the anterior superior mediastinum despite an unrevealing thyroid ultrasound; 18F-FCH PET/CT localized it.

Diagnostic / clinical pearl

When ultrasound is unrevealing but ectopic parathyroid disease remains suspected, 18F-FCH PET/CT may help localize a lesion and guide excision.

Source

PubMed · PMID 42411753

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nuclear Medicine

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.